肌萎缩侧索硬化
谷氨酸受体
代谢型谷氨酸受体
NMDA受体
神经科学
生物
神经传递
内科学
内分泌学
医学
受体
疾病
作者
Aldina Venerosi,Alberto Martire,Angela Rungi,Massimo Pieri,Antonella Ferrante,Cristina Zona,Patrizia Popoli,Gemma Calamandrei
标识
DOI:10.1002/mnfr.201000296
摘要
Abstract Scope: We hypothesized that chronic supplementation with branched chain amino acids (BCAAs) affects neurobehavioral development in vulnerable gene backgrounds. Methods and results: A murine model of amyotrophic lateral sclerosis (ALS), G93A mice bearing the mutated human superoxide dismutase 1 (SOD1) gene, and control mice received from 4 to 16 wk of age dietary supplementation with BCAAs at doses comparable to human usage. Motor coordination, exploratory behaviors, pain threshold, synaptic activity and response to glutamatergic stimulation in primary motor cortex slices were evaluated between the 8th and 16th week. The glial glutamate transporter 1 (GLT‐1) and metabotropic glutamate 5 receptor (mGlu5R) were analyzed by immunoblotting in cortex, hippocampus and striatum. BCAAs induced hyperactivity, decreased pain threshold in wild‐type mice and exacerbated the motor deficits of G93A mice while counteracting their abnormal pain response. Electrophysiology on G93A brain slices showed impaired synaptic function, reduced toxicity of GLT‐1 blocking and increased glutamate toxicity prevented by BCAAs. Immunoblotting indicated down‐regulation of GLT‐1 and mGlu5R in G93A, both effects counteracted by BCAAs. Conclusion: These results, though not fully confirming a role of BCAAs in ALS‐like etiology in the genetic model, clearly indicate that BCAAs' complex effects on central nervous system depend on gene background and raise alert over their spread use.
科研通智能强力驱动
Strongly Powered by AbleSci AI